Eleven Eleven

Telomir Pharmaceuticals Inc (NASDAQ:TELO) Idea

September 9, 2025
oneonecap.com info@oneonecap.com
Isaac Frankel isaac@oneonecap.com

Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing Telomir-1, an oral small molecule designed to combat aging and age-related diseases by targeting fundamental cellular mechanisms including telomere lengthening, metal ion regulation, and oxidative stress reduction. The company went public in February 2024, and is currently preparing for its first Investigational New Drug (IND) application with human clinical trials planned for the first half of 2026.

Telomir-1

Telomir-1 is designed as a multi-mechanism small molecule that addresses five fundamental drivers of aging and chronic disease:

1. Telomere lengthening and protection - Stimulates telomerase activity to restore protective chromosome caps
2. Metal ion regulation - Controls excess iron and copper that contribute to oxidative stress
3. Oxidative stress reduction - Normalizes reactive oxygen species (ROS) levels
4. Mitochondrial function restoration - Improves cellular energy production
5. Calcium balance restoration - Corrects signaling pathways linked to neurodegeneration

Preclinical Research Progress

Aging and Longevity Studies:

- Mouse studies showed 10-fold increase in telomere counts within 10 days of treatment, restoring mobility and cognitive function
- Progeria models demonstrated lifespan restoration and normalization of accelerated aging in C. elegans
- Age-related macular degeneration studies showed vision restoration and retinal regeneration in zebrafish models

Cancer Research:

- Prostate cancer studies showed approximately 50% reduction in tumor volume
- Recent data demonstrated complete reversal of epigenetic gene silencing in aggressive cancer cells, outperforming established drugs like Paclitaxel and Rapamycin

Eleven Eleven

Comparison to Competitors

How Telomir's Anti-Aging Approach Is Different

- Direct Telomere Biology Modulation: Telomir-1 stimulates telomerase to lengthen telomeres, a fundamental process tied to cellular aging, rather than focusing only on downstream pathways or symptom management.
- Multi-Mechanistic Method: Unlike most anti-aging rivals (such as those working on epigenetic reprogramming, senolytics, or metabolic enhancement), Telomir-1 also regulates metal ions (copper, iron, zinc), restores mitochondrial function, addresses oxidative stress, and normalizes calcium signaling.
- Comprehensive Cellular Repair: The aim is broader than treating one disease, targeting the "root cause" mechanisms of aging in various tissues, with preclinical data supporting effects in rare genetic diseases (e.g., Progeria, Wilson's), age-related macular degeneration, and diabetes.

Most anti-aging biotechnology competitors focus on:

- Epigenetic reprogramming
- Senescent cell removal
- Specific gene editing or single molecular targets

Telomir is among the few taking a holistic but direct telomere-restoration path, with a multi-pronged biochemical strategy.

How Telomir's Cancer Approach Is Different

- Restoring Epigenetically Silenced Tumor Suppressors: In preclinical cancer models, Telomir-1 fully reverses gene methylation of key tumor suppressors (such as STAT1 and CDKN2A), reactivating pathways that cancer cells often shut down.
- Dual Action, Anti-Tumor and Organ Protection: Telomir-1 not only reduces tumor size (~50% in animal prostate cancer models) but also prevents chemotherapy-induced toxicity and mortality, something traditional telomere agents and many standard chemotherapies do not do.
- Selective Targeting: While telomerase activators have historically raised concerns about cancer risk, Telomir-1's data show suppressed tumor growth, suggesting a more nuanced telomere modulation that doesn't endanger normal cells.

In contrast, most other cancer-focused biotech firms:

- Pursue immune checkpoint inhibition, targeted synthetic molecules, or pure cytotoxic agents
- Rarely directly reprogram silenced tumor suppressors via epigenetic restoration or simultaneous telomere repair

Current Development

- End of 2025: IND application submission to FDA
- Q2 2025: IND-enabling safety studies initiation

- First half of 2026: First-in-human clinical trials begin

Regulatory Strategy

- Rare Disease Focus: Targeting conditions like Wilson's disease, Progeria, and Werner syndrome for potentially accelerated approval pathways
- FDA RDEA Pilot Program: Participation planned for rare disease endpoint advancement
- Multiple Indication Strategy: Developing Telomir-1 for various conditions to maximize commercial potential

Intellectual Property and Licensing

Telomir operates under an exclusive licensing agreement with MIRALOGX, LLC, an intellectual property development company owned by Williams Sr.:

- Royalty Structure: 8% running royalty on net sales of licensed products
- Territory: Worldwide exclusive rights for human applications
- Patent Status: Patent Cooperation Treaty (PCT) application filed by MIRALOGX

Market Outlook

The global longevity and anti-senescence therapy market was valued at $25.1 billion in 2020 and is projected to reach $44.2 billion by 2030, representing a CAGR of 6.1%. The osteoarthritis market alone is estimated at $7.4 billion worldwide with an expected CAGR of 8.5% through 2030.

Research Collaborations

- Johns Hopkins School of Medicine
- InSilicoTrials: AI modeling and drug development
- Charles River Laboratories: Preclinical testing
- SmartAssays: In vitro studies
- Nagi Bioscience SA: Progeria research collaboration

Risks

Scientific and Regulatory Risks

- Preclinical Stage: No human safety or efficacy data available
- Complex Mechanism: Multi-target approach increases development complexity
- Regulatory Uncertainty: FDA approval pathway not guarantee

Financial Risks

- Going Concern: Substantial doubt about ability to continue operations without additional funding

- High Burn Rate: Increasing operational expenses with no revenue
- Dilution Risk: Likely need for significant additional equity financing

Investment Thesis

Potential Catalysts

Near-term (2025-2026):

- IND application submission and FDA feedback
- Additional preclinical data readouts
- Strategic partnerships or licensing deals
- First-in-human trial initiation

Long-term:

- Clinical trial results across multiple indications
- Regulatory approvals in rare diseases
- Commercial partnerships and revenue generation

Telomir Pharmaceuticals presents a high-risk, high-reward investment opportunity within the rapidly expanding longevity and anti-aging biotech sector. The company's preclinical data is promising, showing potential to address major unmet medical needs across cancer, aging-related diseases, and other chronic conditions. However, it's important to recognize that Telomir’s technology remains unproven in humans at this stage, and there is no guarantee of success in future clinical trials or regulatory approvals - a central reason for the elevated risk profile.

If Telomir’s lead candidate, Telomir-1, successfully advances through clinical development and secures regulatory approval, the commercial potential could be transformational, given the massive market for therapies targeting aging and incurable diseases. However, the path forward is highly uncertain, with significant scientific, financial, and regulatory hurdles to overcome, as is the case for all companies in this space. For those prepared to accept volatility and risk, Telomir offers meaningful upside, but it should be approached with caution and seen as a speculative investment.